Enzyvant Resubmits RVT-802 BLA Learn more

Author Archives:

Not Found

Apologies, but no results were found for the requested archive. Perhaps searching will help find a related post.


No posts found!

Enzyvant Appoints Jeb Ledell as Chief Operating Officer

Enzyvant Newsrooom | October 2019

Reading Time: 2 minutes

Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer

Enzyvant Newsrooom | February 2019

Reading Time: 2 minutes

Enzyvant Receives FDA Rare Pediatric Disease Designation for Investigational Therapy RVT-802

Enzyvant Newsrooom | September 2017

Reading Time: 3 minutes

Rare Disease Day

Enzyvant Newsrooom | February 2017

Reading Time: < 1 minute

RARE in the Square

Enzyvant Newsrooom | January 2017

Reading Time: < 1 minute

Enzyvant to Develop Novel Biologic Therapy for Complete DiGeorge Syndrome

Enzyvant Newsrooom | January 2017

Reading Time: 2 minutes

Contact us for more information